Know the Latest About COVID-19 Monoclonal Antibodies
Rising cases will renew focus on COVID-19 monoclonal antibodies (casirivimab/imdevimab, etc) for treating mild to moderate illness.
Patients. Expect your hospital to follow emergency use authorization (EUA) criteria for COVID-19 "mabs" in most cases.
This means usually dispensing them for COVID-19 OUTpatients age 12 or older...with mild to moderate symptoms for less than 10 days...and at high risk of severe COVID-19 (diabetes, etc).